IMR Press / FBL / Volume 4 / Issue 4 / DOI: 10.2741/bitton

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Gene therapy approaches to HIV-infection: immunological strategies: use of T bodies and universal receptors to redirect cytolytic T-cells
Show Less
1 Laboratoire d'Immunologie Cellulaire, CERVI, UMR CNRS 7627, Hopital Pitie-Salpetriere, 83, Bd. de l’Hopital, 75013 Paris, France
2 Department of Chemical Immunology, The Weizmann Institute of Science Rehovot 76100, Israel
Front. Biosci. (Landmark Ed) 1999, 4(4), 386–393;
Published: 1 April 1999

Combined regimens of classical antiviral treatments have not, until now, lead to the eradication of HIV-1. A specific anti-HIV immune response may have to be boosted or transferred to patients after suppression of viral replication, in order to eradicate residual infected cells from their sanctuaries. Cytotoxic T cells engineered to express recombinant chimeric receptors can be redirected against HIV-infected cells and could represent the basis of a new type of immunotherapy. Several HIV epitopes have been targeted successfully in vitro. Two types of binding domains (antibody fragments, CD4) fused with various signal transducing units (zeta chain of the CD3 complex, Fc epsilon RI gamma chain) have been tested for their ability to redirect effector cells to HIV infected lymphocytes. CD4-zeta-expressing myeloid and natural killer cells conferred SCID mice protection against challenge with tumor cells expressing HIV-env. Finally, the safety of the adoptive transfer of syngeneic CD4-zeta -modified T cells in HIV-infected individuals is currently under evaluation.

Recombinant TCR
Single chain fragment variable
Back to top